Home > Insider Trading > Filing (0001209191-22-055808)

Filing Details

Accession Number:: 0001209191-22-055808
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-11-04 16:30:49
Reporting Period:: 2022-11-02

Accepted Time:: 2022-11-04 16:30:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1815442	Kymera Therapeutics Inc.	KYMR	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1628098	Atlas Venture Fund X, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1742765	Atlas Venture Associates X, Llc	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1742766	Atlas Venture Associates X, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1759241	Atlas Venture Opportunity Fund I, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1780065	Atlas Venture Associates Opportunity I, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1780066	Atlas Venture Associates Opportunity I, Llc	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-11-02	96,581	$30.02	5,440,875	No	4	S	Direct
Common Stock	Disposition	2022-11-02	27,038	$30.02	1,022,502	No	4	S	Indirect	See footnote
Common Stock	Disposition	2022-11-03	75,312	$30.00	5,365,563	No	4	S	Direct
Common Stock	Disposition	2022-11-03	21,085	$30.00	1,001,417	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	See footnote
No	4	S	Direct
No	4	S	Indirect	See footnote

Footnotes

Shares were sold pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.61 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.
The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.